MANCHESTER UNITED Earnings Results: $MANU Reports Quarterly Earnings

Manchester United ($MANU) reported a Q1 2025 loss of $0.03 per share, beating estimates of -$0.22, while revenue of $149.2 million missed estimates of $162.3 million. Institutional investor activity was mixed, with INFINITUM ASSET MANAGEMENT increasing its stake by 4,473,300 shares and SENVEST MANAGEMENT, LLC liquidating its entire position of 1,488,989 shares. Analyst ratings are currently positive, with UBS issuing a "Buy" rating in December 2024.

Analysis

Manchester United ($MANU) presented a mixed financial picture in its Q1 2025 earnings report, with earnings per share of -$0.03 significantly outperforming analyst expectations of -$0.22 by $0.19. However, this positive earnings surprise was contrasted by a revenue shortfall, as the company reported $149.22 million, missing the consensus estimate of $162.31 million by $13.09 million. Institutional investor sentiment appears divided; while 50 institutions added MANU shares to their portfolios, 57 decreased their positions in the most recent quarter. Notably, INFINITUM ASSET MANAGEMENT, LLC made a substantial addition of 4,473,300 shares (+1209.0%), valued at approximately $58.56 million. Conversely, SENVEST MANAGEMENT, LLC and ALYESKA INVESTMENT GROUP, L.P. liquidated their entire stakes of 1,488,989 and 215,531 shares respectively in Q1 2025, while NOMURA HOLDINGS INC exited its 634,627 share position in Q4 2024. LINDSELL TRAIN LTD also reduced its holding by 12.5%. Despite the revenue miss and mixed fund activity, analyst coverage remains constructive, with UBS issuing a "Buy" rating on December 17, 2024. The overall sentiment for this news is categorized as mixed with a moderate potential market impact.

Key Decisions for Investors

• Investors should critically assess the divergence between Manchester United's earnings beat and its revenue miss, as sustained revenue underperformance could challenge future profitability despite cost management.
• The mixed institutional holdings, featuring significant new investments like INFINITUM's alongside complete divestitures by firms such as SENVEST and NOMURA, warrants close observation of upcoming 13F filings to gauge evolving sentiment among large investors.
• The existing 'Buy' rating from UBS offers a degree of support, but investors should monitor subsequent revenue figures and management commentary closely to ascertain if the current top-line weakness is transient or indicative of deeper operational challenges before making significant allocation changes.